EP1401456A4 - Method fron determining the efficacy of reverse cholesterol transport enhancing agents - Google Patents

Method fron determining the efficacy of reverse cholesterol transport enhancing agents

Info

Publication number
EP1401456A4
EP1401456A4 EP02725010A EP02725010A EP1401456A4 EP 1401456 A4 EP1401456 A4 EP 1401456A4 EP 02725010 A EP02725010 A EP 02725010A EP 02725010 A EP02725010 A EP 02725010A EP 1401456 A4 EP1401456 A4 EP 1401456A4
Authority
EP
European Patent Office
Prior art keywords
fron
efficacy
determining
enhancing agents
cholesterol transport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02725010A
Other languages
German (de)
French (fr)
Other versions
EP1401456A1 (en
Inventor
Samuel D Wright
Tian-Quan Cai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1401456A1 publication Critical patent/EP1401456A1/en
Publication of EP1401456A4 publication Critical patent/EP1401456A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP02725010A 2001-02-21 2002-02-19 Method fron determining the efficacy of reverse cholesterol transport enhancing agents Withdrawn EP1401456A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27035601P 2001-02-21 2001-02-21
US270356P 2001-02-21
PCT/US2002/005722 WO2002067958A1 (en) 2001-02-21 2002-02-19 Method for determining efficacy of reverse cholesterol transport enhancing agents

Publications (2)

Publication Number Publication Date
EP1401456A1 EP1401456A1 (en) 2004-03-31
EP1401456A4 true EP1401456A4 (en) 2005-04-20

Family

ID=23030997

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02725010A Withdrawn EP1401456A4 (en) 2001-02-21 2002-02-19 Method fron determining the efficacy of reverse cholesterol transport enhancing agents

Country Status (4)

Country Link
EP (1) EP1401456A4 (en)
JP (1) JP2004527737A (en)
CA (1) CA2438899A1 (en)
WO (1) WO2002067958A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120994A (en) * 1997-05-23 2000-09-19 Queen's University At Kingston Antioxidant responsive element

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ275054A (en) * 1993-11-08 1997-04-24 Peptide Delivery Systems Pty L Diagnosing atherosclerosis or coronary artery disease using labelled composition which mimics essential features of an exogenous lipoprotein
ES2374621T3 (en) * 1997-04-02 2012-02-20 The Brigham And Women's Hospital, Inc. MEANS TO ASSESS THE RISK PROFILE OF AN INDIVIDUAL OF SUFFERING AN ATEROSCLEROTIC DISEASE.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120994A (en) * 1997-05-23 2000-09-19 Queen's University At Kingston Antioxidant responsive element

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200048, Derwent World Patents Index; Class B04, AN 1999-229918, XP002317740 *
See also references of WO02067958A1 *
SUGIYAMA T ET AL: "Soluble CD14 mediates efflux of phospholipids from cells.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 JAN 2001, vol. 166, no. 2, 15 January 2001 (2001-01-15), pages 826 - 831, XP002317739, ISSN: 0022-1767 *
WURFEL MARK M ET AL: "Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 181, no. 5, 1995, pages 1743 - 1754, XP002317741, ISSN: 0022-1007 *

Also Published As

Publication number Publication date
EP1401456A1 (en) 2004-03-31
WO2002067958A1 (en) 2002-09-06
JP2004527737A (en) 2004-09-09
CA2438899A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
DE60229476D1 (en) Biosensor
EP1318396A4 (en) Biosensor
EP1353169A4 (en) Biosensor
EP1445605A4 (en) Biosensor
SG103872A1 (en) Shift register and method of driving the same
EP1421371A4 (en) Biosensor
EP1423399A4 (en) Hydroxypyridonate and hydroxypyrimidinone chelating agents
PL350918A1 (en) Method of enhancing the efficacy of anti-tumor agents
EP1442299A4 (en) Assay
EP1452856A4 (en) Biosensor
IL160539A0 (en) Anti-influenzal agents
EP1401456A4 (en) Method fron determining the efficacy of reverse cholesterol transport enhancing agents
EP1361283A4 (en) Novel assay method
EP1270737A4 (en) Preincubation assay method
GB0123178D0 (en) Joining method
GB0101313D0 (en) Assay
GB2379444B (en) Assay Method
GB0127344D0 (en) Assay method
EP1412754A4 (en) Diagnostic methods and agents
GB0126425D0 (en) The zapper
GB0128321D0 (en) Cleaning method
GB0100782D0 (en) Assay
GB0101312D0 (en) Assay
GB0114309D0 (en) Assay method
GB0128332D0 (en) Cleaning method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030922

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01N 33/50 B

Ipc: 7G 01N 33/92 B

Ipc: 7A 61K 35/60 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050304

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060711